Woodline Partners LP Acquires New Position in Galapagos NV (NASDAQ:GLPG)

Woodline Partners LP acquired a new position in shares of Galapagos NV (NASDAQ:GLPG - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 45,899 shares of the biotechnology company's stock, valued at approximately $1,262,000. Woodline Partners LP owned approximately 0.07% of Galapagos at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the business. R Squared Ltd bought a new stake in Galapagos in the 4th quarter valued at about $26,000. American Century Companies Inc. lifted its position in Galapagos by 5.9% in the 4th quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company's stock valued at $711,000 after purchasing an additional 1,431 shares during the last quarter. QRG Capital Management Inc. lifted its position in Galapagos by 21.7% in the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 1,866 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Galapagos by 45.9% in the 4th quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company's stock valued at $247,000 after purchasing an additional 2,824 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Galapagos by 19.6% in the 4th quarter. Bank of America Corp DE now owns 22,454 shares of the biotechnology company's stock valued at $617,000 after purchasing an additional 3,684 shares during the last quarter. 32.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GLPG. Morgan Stanley downgraded shares of Galapagos from an "equal weight" rating to an "underweight" rating and cut their price objective for the company from $31.00 to $22.00 in a research report on Friday, February 14th. Wall Street Zen downgraded shares of Galapagos from a "hold" rating to a "sell" rating in a research report on Friday, April 25th. Five investment analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. According to MarketBeat, Galapagos has a consensus rating of "Reduce" and a consensus target price of $25.33.

Galapagos Stock Down 0.1%

Shares of GLPG stock traded down $0.03 during trading hours on Friday, reaching $29.06. 102,012 shares of the stock traded hands, compared to its average volume of 239,708. Galapagos NV has a 1-year low of $22.36 and a 1-year high of $31.23. The business has a fifty day moving average price of $25.96 and a 200 day moving average price of $25.99.

Galapagos (NASDAQ:GLPG - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($2.47) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($2.24). The company had revenue of $97.33 million for the quarter, compared to analysts' expectations of $72.22 million. As a group, equities research analysts anticipate that Galapagos NV will post -1.6 EPS for the current year.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.